Breaking News
December 19, 2018 - Researchers uncover genes that play a key role in the inactivation of X chromosomes
December 19, 2018 - The case for the federal minister of health to recall them
December 19, 2018 - Regular theatre and cinema visits keeps depression away in seniors finds study
December 19, 2018 - Personalization techniques give a new lease of life to anticancer vaccines
December 19, 2018 - Research opens door to development of drug or vaccine for late-onset Alzheimer’s
December 19, 2018 - Single workout can boost metabolism for days
December 19, 2018 - UI study leads to better understanding of signaling capacity between neurons
December 19, 2018 - Gut microbiome plays role in immune system regulation, study finds
December 19, 2018 - How MAPK translocation leads to drug resistance in melanoma
December 19, 2018 - Increasing prevalence of antibiotic resistance in the U.S. linked with occasional use
December 19, 2018 - Mind-body exercises may improve cognition in older adults
December 19, 2018 - Hepatitis C drug can eliminate chikungunya, yellow fever virus
December 19, 2018 - Separating male and female mice changes the way they smell, shows study
December 19, 2018 - FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
December 19, 2018 - Mediterranean Diet for Osteoarthritis | About OA
December 19, 2018 - Successful bladder repair using silk fibroid scaffolds
December 19, 2018 - Quidel receives CE mark to use Sofia 2 Lyme+ Fluorescent Immunoassay with Sofia 2 analyzer
December 19, 2018 - Horizon Discovery partners with C4XD to validate novel synthetic lethal oncology targets
December 19, 2018 - Research suggests a promising therapeutic target to treat or prevent metabolic disorders
December 19, 2018 - Split liver transplants could save children on wait list finds study
December 19, 2018 - Michigan-based food manufacturer ordered to discontinue operations after recurrent food safety violations
December 19, 2018 - HPV discovery could lead to new treatments for cervical cancer
December 19, 2018 - Real-time neurofeedback controls Parkinson’s brainwaves
December 19, 2018 - Incorrect prescribing warnings in electronic prescribing systems
December 19, 2018 - New $1.6 million NIH grant supports study on a gene vital to circadian rhythms
December 19, 2018 - Racial Disparities Seen Among Teens Undergoing Flu Vaccination
December 19, 2018 - To resolve inflammation, location matters
December 19, 2018 - Dancing could help older women to perform their daily tasks
December 19, 2018 - Research identifies new therapeutic target for cancer treatment and tissue regeneration
December 19, 2018 - Energy costs, social isolation contribute to health risk of older adults in extreme weather
December 19, 2018 - Potential combination therapy against rare disease of the bone marrow could improve treatment
December 19, 2018 - Researchers aim to improve cognition, reverse weight gain in schizophrenia
December 19, 2018 - UC San Diego Health offers new DRG stimulation device for phantom limb pain
December 19, 2018 - Study examines relationship between growth restriction and risk of childhood mortality
December 19, 2018 - New study provides insights on increased risk of suicide in young patients visiting ED
December 19, 2018 - AHA: Thyroid Problems Linked to Worsening Heart Failure
December 19, 2018 - World-first coeliac disease vaccine enters Phase 2 trials
December 19, 2018 - RNA sequencing offers novel insights into the microbiome
December 19, 2018 - A promising, effective vaccine for common respiratory disease
December 19, 2018 - Protein may slow progression of emphysema, study finds
December 19, 2018 - Studying atrial fibrillation — and exploring new frontiers in precision health
December 19, 2018 - A New Way To Get College Students Through A Psychiatric Crisis — And Back To School
December 19, 2018 - Optum, UnitedHealthcare take action to help people affected by North Carolina winter storms
December 18, 2018 - Weight change in middle-aged, elderly Chinese Singaporeans related to increased risk of death
December 18, 2018 - Immune cells sacrifice themselves to protect us from invading bacteria
December 18, 2018 - Watching brain cells fire, with a twist of gravitational waves
December 18, 2018 - 2018 in Review
December 18, 2018 - Getting the Most Out of the CLARITY Technique
December 18, 2018 - NVF shoes provide a viable option for track and road racing
December 18, 2018 - CRISPR may restore effectiveness of chemotherapies used to treat lung cancer
December 18, 2018 - New app accurately measures and charts progression of skin wounds
December 18, 2018 - Persistent Discrimination ID’d Among Physician Mothers
December 18, 2018 - Cellphone technology developed to detect HIV
December 18, 2018 - A Stanford doctor hits the field with the 49ers — as their airway management physician
December 18, 2018 - The Rise of Anxiety Baking
December 18, 2018 - Just one night of sleep deprivation increases the urge to eat
December 18, 2018 - Study reveals mechanism behind failed remyelination in MS
December 18, 2018 - New genetic testing method increases the precision of biomarker analysis
December 18, 2018 - Simple technique to effectively treat underdiagnosed cause of debilitating chest pain
December 18, 2018 - Barbershop-based medical intervention can successfully lower blood pressure, new data shows
December 18, 2018 - Food labels have caused changes in consumers’ intake and industry’s use of key additives
December 18, 2018 - Sickest children could benefit from split liver transplants
December 18, 2018 - Scientists create patient-specific model to identify most effective treatment for appendix cancer
December 18, 2018 - ‘Little Foot’ endocast reveals a small brain combining ape-like and human-like features
December 18, 2018 - New therapy for childhood blindness shows ‘very promising’ results
December 18, 2018 - Researchers discover promising new compound against Buruli ulcer
December 18, 2018 - Study finds significant use of traditional, complementary and alternative medicines in Sub-Saharan Africa
December 18, 2018 - California Farm Implicated in Outbreak of E. coli Tied to Romaine Lettuce
December 18, 2018 - Mobile health has power to transform HIV/AIDS nursing
December 18, 2018 - Celiac Vaccine in Clinical Trials at Columbia
December 18, 2018 - Research into mental health first aid prompts practical guidance and resources for workplace
December 18, 2018 - Researcher conducts study to investigate peripheral blood markers of Alzheimer’s disease
December 18, 2018 - Researchers identify link between mucus in the small airways and pulmonary fibrosis
December 18, 2018 - EU Commission’s Health Policy Platform to host EKHA program on transplantation
December 18, 2018 - Survivors of childhood Hodgkin lymphoma have high risk of developing solid tumors
December 18, 2018 - Small changes to cafeteria design can get kids to eat healthier, new assessment tool finds
December 18, 2018 - From Machines to Cyclic Compounds
December 18, 2018 - New study reveals best assessment tools to establish delirium severity
December 18, 2018 - Rice University scientists develop synthetic protein switches to control electron flow
December 18, 2018 - Home-based pulmonary function monitoring for teens with Duchenne muscular dystrophy
‘Cutting edge’ CAR T cell immunotherapy approved in England. But is the NHS ready?

‘Cutting edge’ CAR T cell immunotherapy approved in England. But is the NHS ready?

image_pdfDownload PDFimage_print
Credit: CC0 Public Domain

Today, a new blood cancer treatment was approved for use on the NHS in England. And in early September, NHS England announced another, similar treatment will be available to some children and young people with a different type of blood cancer.

As with any new drug approval, these announcements are great news for the patients who may benefit. But these are no ordinary drugs.

The two treatments – called axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) respectively – have attracted attention because of the ground-breaking way in which they’re made and work.

This makes their approval a fascinating live case study for an NHS that’s attempting to position itself as a world-leader in cancer treatment.

What is CAR T cell therapy?

Yescarta and Kymriah are two of a new line of immune-boosting treatments called CAR T cell therapies.

They involve extracting specialised immune cells, called T cells, from a patient’s blood and altering them in the lab so they recognise and fight cancer cells. The modified T cells are multiplied a thousand-fold in the lab and then put back into the patient’s bloodstream.

The results from small trials have been promising, as the cellular engineering turns patients’ own immune systems into precise anti-cancer weapons. And unlike standard chemotherapy, the treatment only has to be given once.

CAR T cells are “the first truly personalised therapy, because the cells come from the patient,” says Professor Karl Peggs, a Cancer Research UK-funded immunotherapy expert. He says this makes it a game-changer “in the small niche in which it is being licensed and used”.

In other words, while the technology is exciting, at the moment it will only reach a relatively small number of people, and that’s unlikely to change any time soon.

In fact, Peggs cautions against overplaying the potential for CAR T to turn blood cancer treatment on its head. For childhood acute lymphoblastic leukaemia – one of the cancer types CAR T can now be used in – he says only a tiny fraction of patients will benefit from the new treatment because “most patients are cured with conventional therapy”.

But for the few patients in whom chemotherapy hasn’t worked, the approval of CAR T offers a vital new option.

How effective is CAR T?

Impressive results have been reported in clinical trials for some types of blood cancer where there are few other treatment options available. In one trial, around 8 in 10 patients saw their disease respond to the treatment, and for around half of those patients their cancer hadn’t come back a year later.

But, while the treatment has shown great promise, it doesn’t work for everyone. According to Peggs, it’s unknown why only some patients’ cancers respond initially, and why others see their cancer come back later while some remain disease free.

More research will help answer these questions, and the terms of the treatments’ approval on the NHS state that data on their effectiveness can be collected along the way. This, again, is positive news.

The potency of unleashing the immune system also brings with it the risk of serious side effects that need expert care. In one clinical trial testing Yescarta, 94 percent of patients experienced a side effect called cytokine release syndrome, and 1 in 7 of them needed treatment in intensive care.

Despite the challenges, these treatments have attracted a lot of interest. The head of the NHS in England, Simon Stevens, has described CAR T therapy as “cutting edge” and “one of the most innovative treatments ever offered on the NHS”.

But the complexity of these treatments means they pose more of a challenge to the NHS than most new drugs.

Is the NHS ready for CAR T therapies?

“In many ways, this treatment is more akin to a stem cell transplant than traditional chemotherapy,” says Peggs. NHS England has selected hospitals where staff have experience of procedures like stem cell or bone marrow transplants as the first locations to offer the treatment. The NHS is already in a strong position, as it has world-class facilities for carrying out these procedures.

But those hospitals will also have to plan for patients’ supportive care. To help monitor side effects, people having CAR T therapy will have to stay in hospital afterwards, and be within easy travelling distance for several weeks after they leave.

This means the treatment will initially only be given to a few patients at a time across England, in a limited number of hospitals, to make sure the NHS can look after them properly.

It’s not yet clear whether patients in Wales and Northern Ireland will need to travel to hospitals in England to be treated. And in Scotland, on top of this uncertainty, these treatments would also have to be separately approved by the Scottish Medicines Consortium (SMC) before they can receive NHS funding. The SMC is due to decide on Yescarta in November, and on Kymriah in early 2019.

Complexity aside, one of the major debates surrounding CAR T cell therapies has been their cost. The treatments are expensive, at around £280,000 per patient, though the NHS has negotiated significant discounts for both Yescarta and Kymriah. Both the NHS and the companies that develop these treatments, Gilead and Novartis, deserve huge credit for agreeing deals for these drugs.

CAR T therapy is an extreme example of a general trend for the newest cancer drugs, which are more personalised and complex, but pricier as a result. This trend makes it vital the NHS explores new ways of paying for cancer drugs, which could make it easier to approve exciting new treatments in future so that patients can access them more quickly.

We’re working with partners in Greater Manchester to explore one approach called outcomes-based pricing, where the NHS pays a different price for the drug, based on the benefits it gives patients.

What does this all mean for patients and the NHS?

The NHS approvals of Kymriah and Yescarta are a huge leap forward for those patients in England with the very specific blood cancers they are approved to treat.

But even for these patients, there are still unanswered questions about the drugs’ long-term effectiveness, which patients are most likely to respond, and how to manage and reduce side effects. We, and others, are hoping to answer these questions through research.

The NHS can rightly be proud that a small number of patients in England will be the first in Europe to have routine access to this highly complex technology. But the challenges presented by exciting new treatments like CAR T won’t go away. Today’s good news should be just the start, not the end, of the NHS’s preparations for this shift.

Explore further:
Engineered cell therapy rejected for aggressive adult lymphoma on NHS in England

Provided by:
Cancer Research UK

Tagged with:

About author

Related Articles